1. I think this type of financing is a last resort and

New Post Public Reply Private Reply Replies (1) Message Board
MoneyTree donnellymp #18822
1. I think this type of financing is a last resort and it’s either take it or financially the company cannot continue to operate. I don’t think uplisting will solve this problem. We need money to operate and the only way to stop using “toxic” funding is to get funding through lympro revenue, grants, or sale of parts or all of the diagnostic division. Until then we will remain in somewhat of a survival mode.

2. Dilution is a consequence of the toxic financing. In the absence of other funding, selling shares of the company to the toxic financiers is how we get money from them. We are using this money to create more wealth in the future by buying new products and funding continuing research on our own products. Short term pain for long term gain. I think that theoretically splits are mostly psychological. There are some tangible effects like certain funds being able to buy once we reach certain share prices. But in general I think reverse splits “look bad” because it is an inorganic measure used to raise the share price, and it results in share holders’ share count being reduced. While the value of their investment should stay the same, it’s still a psychological “bummer”. It will probably attract a more diverse group of investors who wouldn’t otherwise take one look at a penny stock, so that’s good. A forward split, in contrast looks good because of all the opposite reasons. Your share count increases, and you are lowering the share price because it’s getting too high to attract some investors. What a nice problem to have when your share price is getting too high .

3. My personal investment horizon is long term. I have about half of my shares in Roth account, and I really don’t plan on touching those shares for the foreseeable future, 10+ years. The other half of my investment I will probably reevaluate in around 5 years.

4. I like the additions we’ve made to the pipeline with ESS, MS Precise, and the pending Georgetown option. I think they each have significant potential. I have been pretty underwhelmed by lympro, but hopefully that turns around with time, although the latest numbers do not seem promising. Funding for the additions is still a concern of mine but in the event that any one of them successfully makes it to market it should more than make up for the initial investment for all of them combined.

5. This doesn’t make a difference to me, personally. I think he’s doing what he has to do to keep the company afloat. I have felt misled by him at times but I don’t know what the alternative would be. More honesty and openness would be appreciated at a personal level, but I don’t think our current financiers would care for anything but public optimism from the face of the company, and right now we are dependent on them.

6. I think any money coming in decreases our dependence on toxic financing, which is a good thing. I would rather sell that diagnostic division with royalties than spin it off but I am pretty ignorant in this area and sale just seems cleaner and simpler than a spin off.

8. I think if we can get to a point where a 10:1 or smaller split I would be happy. I really can’t tell how high a priority uplisting is since they’ve been saying they’ve been saying they are going to do it for the last two years. I’m hopeful they will continue to be patient with it until there will be no more than a 25:1 split. If we were to somehow, miraculously uplist without a reverse split I would think it would take at least another two to three years with MANF showing very positive clinical results and being fast tracked by the FDA, combined with our other products bringing in enough revenue to not only finance all the trials, but to be profitable as a company. It could happen, but I’m not counting on it. I see this happening in more of a 5 to 7 year time frame.

I think the company is really focused on trying to find non-dilutive ways to fund MANF trials. I think Lympro was plan A, and while it may still work out, we are in the process of starting plan B with the new acquisitions, just in case plan A doesn’t work out as well as originally thought. Until we get something to work, we have no choice but to continue to use less than desirable methods of financing the company. The issues of dilution and using a reverse split to uplist are, to me, things short term holders should be concerned about, but will iron themselves out over the long term. I think our pipeline is very impressive, and has more potential than any other I am aware of. I think 5 years is a minimum to see any MANF products make it to market. But I think between Lympro and the Georgetown test, ESS, and MS Precise, we will be sitting pretty within 5 years. Then there is always Phenoguard. And that is just the stuff we know about. I’m sure future will hold many surprises both good and bad. At the end of the day it’s a pretty big risk with the potential to change the lives of patients and investors alike. If you’re in this stock at least your willing to take a chance to change your life, rather than just settling for the status quo. I’ll leave you with a quote of Theodore Roosevelt, that I think applies quite nicely.

"It is not the critic who counts; not the man who points out how the strong man stumbles, or where the doer of deeds could have done them better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood; who strives valiantly; who errs, who comes short again and again, because there is no effort without error and shortcoming; but who does actually strive to do the deeds; who knows great enthusiasms, the great devotions; who spends himself in a worthy cause; who at the best knows in the end the triumph of high achievement, and who at the worst, if he fails, at least fails while daring greatly, so that his place shall never be with those cold and timid souls who neither know victory nor defeat."

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 60

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 55

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
tion End -->

Top 5 Most Recently Viewed Articles

Lenders Cooperative Enhances SBA Lending with Expert Chuck Evans

Updated Category News Views 259

Lenders Cooperative brought Chuck Evans on board back in early 2024 to shake things up in the SBA lending arena. As interest rates soared, traditional lenders were already feeling the pinch—like a boxer with a weight on their gloves. And you know how it goes when your usual funding sources start tightening up; that’s when you see firms scrambling to adapt. What Went...

Continue Reading
Bifrost Secures $8M to Enhance AI Solutions for Real-World Impact

Updated Category News Views 252

Bifrost AI Achieves $8 Million Series A Funding Bifrost AI, an innovative player in the Generative 3D Data space, has successfully raised 8 million dollars in Series A funding. This achievement marks a significant milestone in its journey to meet the increasing demand for AI training data and realistic 3D simulations. Transforming the AI Landscape with Advanced Data...

Continue Reading
Enhancing Customer Experiences: GTS's AI-Driven Solutions

Updated Category News Views 188

Transforming Contact Centers with GTS's Innovative Solutions What does it take to transform a contact center into a vibrant hub for exceptional customer experiences? At Global Technology Solutions (GTS), we help businesses answer this vital question with AI-powered tools and innovative strategies every day. In today’s digital age, contact centers play a pivotal role in...

Continue Reading
Breakthrough Study on Neural Tube Defects Uncovers Gene Links

Updated Category News Views 191

Groundbreaking Research on Neural Tube Defects Recent advancements in genetic research have shed new light on neural tube defects (NTDs), a significant challenge in the field of congenital conditions. Bionano Genomics, Inc. (NASDAQ: BNGO) and the Greenwood Genetic Center (GGC) have collaborated in publishing a pivotal study in Genome Research. This innovative research...

Continue Reading
La-Z-Boy Faces Q1 Earnings Setback, Plans for Better Future

Updated Category News Views 167

La-Z-Boy Inc Reports Q1 Earnings Challenges La-Z-Boy Inc (NYSE: LZB) is facing a tough time with its latest financial results, leading to a decline in its stock value. On a recent Tuesday, shares fell significantly after the company disclosed its first-quarter results for the fiscal year. Q1 Performance Overview For the first quarter, La-Z-Boy reported revenue of $492.22...

Continue Reading